Last checked at 27 Nov 2020 15:08
Ovoca Bio plc
("Ovoca" or the "Company")
Notice of Annual General Meeting
Dublin, Ireland, 27 November, 2020 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that the 2020 Annual General Meeting ("AGM") of the Company will be held at the registered office of the Company, 17 Pembroke Street Upper, Dublin 2, Ireland at 11.00am on 17 December 2020. The Notice of AGM, containing details of the resolutions to be proposed at the AGM, has been published and posted to shareholders and is also available on the Company's website at www.ovocabio.com.
COVID-19
Due to the continuation of the Irish Government's Covid-19 restrictions in relation to public gatherings and to prioritise the health and safety of our shareholders, employees and other stakeholders, the Board is requesting that shareholders do not physically attend the AGM and instead submit a proxy form in favour of the Chairman to ensure they can vote and be represented at the AGM without attending in person. Further information on how to appoint a proxy and the timelines by which proxies must be received are contained in the Notice of AGM.
It will be possible to listen to the proceedings of this year's AGM remotely using a teleconference facility provided by the Company. Shareholders will not be able to use this facility to vote, ask questions or table resolutions. Information on how to register for this teleconference facility is available on the Company's website at www.ovocabio.com/agm-registration.
All shareholders will be able to submit questions in advance of the AGM in writing by email to the Company Secretary at info@ovocabio.com to be received no later than 5.00pm on Thursday, 10 December 2020. All correspondence should include sufficient information to identify the shareholders on the Register of Members. Questions submitted using these methods will be addressed by the Chairman at the AGM where possible.
As the situation is evolving and the Irish Government guidance may change, shareholders are encouraged to check the Company's website for any further updates regarding the AGM.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.